Page last updated: 2024-11-10

4-azidosalicylic acid

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

4-azidosalicylic acid: structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID3006162
CHEMBL ID5170640
SCHEMBL ID13653901
MeSH IDM0176146

Synonyms (12)

Synonym
4-azidosalicylic acid
4-azido-2-hydroxy-benzoic acid
salicylic acid, 4-azido-
4-azido-2-hydroxybenzoic acid
FT-0662428
66761-27-1
AKOS006229715
SCHEMBL13653901
mfcd07367665
NLPWSMKACWGINL-UHFFFAOYSA-N
T71197
CHEMBL5170640

Research Excerpts

Bioavailability

ExcerptReferenceRelevance
" para-Aminosalicylic acid (PAS), an important second-line agent for treating drug-resistant Mycobacterium tuberculosis, has moderate bioavailability and rapid clearance that necessitate high daily doses of up to 12 g per day, which in turn causes severe gastrointestinal disturbances presumably by disruption of gut microbiota and host epithelial cells."( Synthesis and biological evaluation of orally active prodrugs and analogs of para-aminosalicylic acid (PAS).
Aldrich, CC; Baughn, AD; Boshoff, HIM; Dartois, V; Hegde, PV; Howe, MD; Jia, Z; Pan, Y; Remache, B; Sharma, S; Zimmerman, MD, 2022
)
0.72

Dosage Studied

ExcerptRelevanceReference
" Among the mono-fluorinated analogs prepared, 5-fluoro-PAS, exhibited the best activity and an 11-fold decreased rate of inactivation by NAT-1 that translated to a 5-fold improved exposure as measured by area-under-the-curve (AUC) following oral dosing to CD-1 mice."( Synthesis and biological evaluation of orally active prodrugs and analogs of para-aminosalicylic acid (PAS).
Aldrich, CC; Baughn, AD; Boshoff, HIM; Dartois, V; Hegde, PV; Howe, MD; Jia, Z; Pan, Y; Remache, B; Sharma, S; Zimmerman, MD, 2022
)
0.72
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (3)

Assay IDTitleYearJournalArticle
AID1879685Ratio of compound AUC to para-aminosalicylic acid AUC in CD-1 mouse2022European journal of medicinal chemistry, Mar-15, Volume: 232Synthesis and biological evaluation of orally active prodrugs and analogs of para-aminosalicylic acid (PAS).
AID1879684Antimycobacterial activity against Mycobacterium tuberculosis H37Rv assessed as inhibition of bacterial growth measured after 10 days by microbroth dilution method2022European journal of medicinal chemistry, Mar-15, Volume: 232Synthesis and biological evaluation of orally active prodrugs and analogs of para-aminosalicylic acid (PAS).
AID1879682AUC in CD-1 mouse at 25 mg/kg, po administered as single dose and measured up to 24 hrs by LC-MS/MS analysis2022European journal of medicinal chemistry, Mar-15, Volume: 232Synthesis and biological evaluation of orally active prodrugs and analogs of para-aminosalicylic acid (PAS).
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (14)

TimeframeStudies, This Drug (%)All Drugs %
pre-19901 (7.14)18.7374
1990's7 (50.00)18.2507
2000's1 (7.14)29.6817
2010's4 (28.57)24.3611
2020's1 (7.14)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.74

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index12.74 (24.57)
Research Supply Index2.77 (2.92)
Research Growth Index5.51 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (12.74)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other15 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]